Skip to content
ClinCalc Pro
Menu
α2 adrenergic agonist Pregnancy: §8.1 Risk Summary verbatim: 'The safety of lofexidine in pregnant women has not been established. In animal reproduction studies, oral administration of lofexidine during organogenesis to pregnant rats and rabbits caused a reduction in fetal weights, increases in fetal resorptions, and litter loss at exposures below that in humans. When oral lofexidine was administered from the beginning of organogenesis through lactation, increased stillbirths and litter loss were noted along with decreased viability and lactation indices. The offspring exhibited delays in sexual maturation, auditory startle, and surface righting. These effects occurred at exposures below that in humans.' No human data are provided and §8.1 was truncated at the source-fetch limit; no lactation section was retrieved.

Lofexidine hydrochloride

Brand names: BritLofex

Lofexidine hydrochloride is a centrally acting alpha-2 adrenergic agonist used to manage the symptoms of opioid withdrawal during detoxification.

Adult dose

Dose: Three 0.18 mg tablets orally (opioid withdrawal)
Route: Oral — 0.18 mg film-coated tablets; §3: 'Each tablet contains 0.18 mg lofexidine (equivalent to 0.2 mg of lofexidine hydrochloride). Tablets: 0.18 mg.'
Frequency: 4 times daily with 5 to 6 hours between each dose, during the period of peak withdrawal symptoms (generally the first 5 to 7 days following last use of opioid); may be continued for up to 14 days with dosing guided by symptoms
Max: Maximum total daily dosage 2.88 mg (16 tablets) and maximum single dose 0.72 mg (4 tablets) — §2.1 verbatim: 'The total daily dosage of lofexidine tablets should not exceed 2.88 mg (16 tablets) and no single dose should exceed 0.72 mg (4 tablets).'
SCOPE: this is the US oral-tablet regimen for the symptomatic management of opioid withdrawal — the page's primary indication and route. Verbatim §2.1: 'The usual lofexidine tablet starting dosage is three 0.18 mg tablets taken orally 4 times daily during the period of peak withdrawal symptoms (generally the first 5 to 7 days following last use of opioid) with dosing guided by symptoms and side effects. There should be 5 to 6 hours between each dose.' Duration and taper: 'Lofexidine tablet treatment may be continued for up to 14 days with dosing guided by symptoms. Discontinue lofexidine tablets with a gradual dose reduction over a 2- to 4-day period to mitigate lofexidine tablet withdrawal symptoms (e.g., reducing by 1 tablet per dose every 1 to 2 days).' Titration down: 'The lofexidine tablet dose should be reduced, held, or discontinued for individuals who demonstrate a greater sensitivity to lofexidine tablets side effects… Lower doses may be appropriate as opioid withdrawal symptoms wane.' Administration: 'Lofexidine tablets can be administered in the presence or absence of food.' ELDERLY (§8.5): 'No studies have been performed to characterize the pharmacokinetics of lofexidine or to establish its safety and effectiveness in geriatric patients. Caution should be exercised when lofexidine is administered to patients over 65 years of age. Dosing adjustments similar to those recommended in patients with renal impairment should be considered.' PAEDIATRIC (§8.4): 'The safety and effectiveness of lofexidine have not been established in pediatric patients' — hence paedDose null; verify any under-18 use against a children's formulary. ⚠️ UK CROSS-CHECK REQUIRED: (BritLofex, expressed as lofexidine hydrochloride); the US figures above are expressed as lofexidine base in 0.18 mg tablets and differ in both strength and daily maximum. Do not merge the two without the UK SPC.

Dose adjustments

Renal

§2.3, Table 2 verbatim — Moderate impairment (estimated GFR 30 to 89.9 mL/min/1.73 m2): '2 tablets 4 times daily (1.44 mg per day)'. Severe impairment, End-Stage Renal Disease, or on dialysis (estimated GFR < 30): '1 tablet 4 times daily (0.72 mg per day)'. Also: 'Lofexidine tablets may be administered without regard to the timing of dialysis.' §5.1 additionally advises avoiding use in patients with chronic renal failure.

Hepatic

§2.2, Table 1 verbatim — Mild impairment (Child-Pugh 5 to 6): '3 tablets 4 times daily (2.16 mg per day)'. Moderate impairment (Child-Pugh 7 to 9): '2 tablets 4 times daily (1.44 mg per day)'. Severe impairment (Child-Pugh > 9): '1 tablet 4 times daily (0.72 mg per day)'. §5.2 additionally recommends ECG monitoring in patients with hepatic impairment.

Dose independently re-sourced from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • None — §4 CONTRAINDICATIONS reads in full: 'None.' (US label). The entries below are §5 avoidance statements, NOT labelled contraindications.
  • Not a contraindication but an avoidance (§5.1): 'Avoid use in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure, as well as in patients with marked bradycardia.'
  • Not a contraindication but an avoidance (§5.2): 'Avoid use in patients with congenital long QT syndrome.'

Side effects

  • §6 most common adverse reactions (incidence ≥ 10% and notably more frequent than placebo): orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth
  • Hypotension, bradycardia and syncope (§5.1) — 'May cause a decrease in blood pressure, a decrease in pulse, and syncope.'
  • QT prolongation (§5.2) — 'Lofexidine prolong the QT interval.'
  • Central nervous system depression (§5.3) — potentiates the CNS depressant effects of benzodiazepines, and may potentiate those of alcohol, barbiturates and other sedating drugs
  • Increased risk of opioid overdose after opioid discontinuation (§5.4) — 'Patients who complete opioid discontinuation are at an increased risk of fatal overdose' (§5 truncated at the source-fetch limit)
  • Discontinuation symptoms (§5.5) — lofexidine withdrawal symptoms if stopped abruptly rather than tapered over 2 to 4 days

Monitoring

  • §5.1: 'Monitor vital signs before dosing and advise patients on how to minimize the risk of these cardiovascular effects and manage symptoms, should they occur. Monitor symptoms related to bradycardia and orthostasis.'
  • §5.1 outpatient use: 'When using in outpatients, ensure that patients are capable of self-monitoring for signs and symptoms.'
  • §5.2 ECG: 'Monitor ECG in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias, hepatic or renal impairment, or in patients taking other medicinal products that lead to QT prolongation.'
  • §7.1 with methadone: 'Lofexidine and methadone both prolong the QT interval. ECG monitoring is recommended in patients receiving methadone and lofexidine concomitantly.'
  • §7.4 with CYP2D6 inhibitors: 'Monitor for symptoms of orthostasis and bradycardia with concomitant use of a CYP2D6 inhibitor' (concomitant paroxetine increased plasma lofexidine levels)

Clinical monograph

How it works

By stimulating central alpha-2 adrenoceptors it reduces sympathetic (noradrenergic) overactivity, easing the autonomic symptoms associated with opioid withdrawal.

Prescribing in practice

  • It can cause hypotension, bradycardia and QT-interval prolongation, so blood pressure and pulse should be monitored and it should be used with caution in cardiovascular disease.
  • Doses should be reduced gradually at the end of treatment, as abrupt withdrawal may cause rebound hypertension.
  • Use with caution in patients with renal impairment or a history of QT prolongation.

Monitoring

Monitor blood pressure and heart rate during treatment and on withdrawal, with attention to symptoms of hypotension and bradycardia.

Counselling the patient

  • Explain that the medicine relieves withdrawal symptoms but is not an opioid substitute.
  • Rise slowly from sitting or lying because of the risk of dizziness.
  • Report fainting, slow heartbeat or palpitations.

Evidence & guidelines

Lofexidine is an established option for managing opioid withdrawal symptoms and is supported by NICE guidance on drug misuse and detoxification.

Reference: NICE CG52; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.